[G25-39] Durvalumab (small cell lung cancer, non-advanced) – Addendum to Project A25-96
Last updated 22.01.2026
Project no.:
G25-39
Commission:
Commission awarded on 09.12.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G25-39
| Project no. | Title | Status |
|---|---|---|
| A25-96 | Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
22-01-2026 A G-BA decision was published.
G-BA documents on this decision